Immediate Impact

50 standout
Sub-graph 1 of 25

Citing Papers

Targeted protein degradation: advances in drug discovery and clinical practice
2024 Standout
CAR T Cells and T-Cell Therapies for Cancer
2024 Standout
2 intermediate papers

Works of Tom Martin being referenced

Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma
2021
Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma
2013

Author Peers

Author Last Decade Papers Cites
Tom Martin 234 170 192 22 355
Francesca Grasso 165 41 193 11 370
Daiki Karigane 135 50 118 30 320
Nicolas Stocker 68 64 123 26 342
Joe N. Frost 174 45 81 18 405
Hannah Brown 38 111 79 34 402
Eric L. Simmons 79 39 71 21 337
Haodong Cai 92 172 153 27 397
Ilana Harari 62 50 160 11 379
M Deschaseaux 89 91 49 15 386
Ann Van de Velde 149 77 123 29 363

All Works

Loading papers...

Rankless by CCL
2026